🎤 Join our founder group to hear from firms like NEA on What it takes to raise a Series A?

Register
Shaquille Vayda

Shaquille Vayda

Partner·Lux Capital

Bay Area, CA, USA

Bio

Professional summary

Shaq Vayda is a Partner at Lux Capital who invests in platform and building-block companies, especially with deeply technical teams from inception. His technical background includes DSP work at NASA and Northrop Grumman on infrared and RF data for missions including the James Webb Space Telescope, as well as genomic-signal work at Illumina and early support for GRAIL’s liquid-biopsy platform. Before Lux, he advised mega-cap private equity investors on enterprise technology and healthcare investments at Parthenon.

Background

Career, education, and skills

Career history

  • Lux CapitalPartnerPresent
  • ParthenonAdvisor to private equity investors
  • IlluminaGenomic signal work
  • GRAILEarly platform support
  • NASA and Northrop GrummanDSP work

Education

  • University of FloridaBS, Mechanical Engineering

Other partners at Lux Capital

12 more profiles

Bilal Zuberi

Bilal Zuberi

Co-President & General Partner

Lux Capital

Bilal Zuberi is associated with Lux Capital as a long-time deeptech investor. Public profiles describe more than a decade as a Lux General Partner, with investments across applied AI, autonomy, industrial technology, hardware, climate, healthcare and other technically ambitious sectors.

DeeptechHardwareIndustrial AI
Brandon Reeves

Brandon Reeves

Partner

Lux Capital

Lux partner investing in AI, software, defense, manufacturing and robotics.

Artificial intelligenceAutonomous systemsDefenseManufacturingRoboticsSoftware
Danny Crichton

Danny Crichton

Partner, Research

Lux Capital

Lux Partner, Research and editor-in-chief, formerly managing editor at TechCrunch.

FinanceMediaResearchRiskgamingScienceTechnology analysis
David K. Yang

David K. Yang

Partner

Lux Capital

Lux life sciences partner focused on therapeutics, R&D tools and biopharma infrastructure.

Biopharma infrastructureBiotechLife sciencesR&D toolsTherapeutics
DS

Deena Shakir

Partner

Lux Capital

Deena Shakir is a Partner at Lux Capital. Her official profile says she invests across stages and sectors, including women's health, digital health infrastructure, health equity, foodtech, and fintech.

Digital health infrastructureFintechFoodtechWomen's health
Firas Atwa

Firas Atwa

Lux Capital

Harvard MBA candidate with prior Algebra Ventures, Swvl, and Alvarez & Marsal experience.

AfricaEmerging marketsEntrepreneurshipFintechStrategyVenture capital
Grace Isford

Grace Isford

Partner

Lux Capital

Lux partner investing in computational sciences, AI applications, and infrastructure software.

AIComputational sciencesInfrastructure softwareLLM applicationsPhysical-world software
Josh Wolfe

Josh Wolfe

Partner and Co-Founder

Lux Capital

Josh Wolfe is Partner and Co-Founder at Lux Capital. His official profile says he helps lead the firm, invests in defense and biotech, and has co-founded more than 20 Lux companies.

AIBiotechRoboticsSpace
Lan Jiang

Lan Jiang

Partner

Lux Capital

Lux partner focused on biotech analytics, ML infrastructure, developer tooling, and AI applications.

AI applicationsBiotech analyticsDeveloper toolingHealthcareMachine learning infrastructurePlatform therapeutics
Laurence Pevsner

Laurence Pevsner

Partner, Research

Lux Capital

Lux research partner focused on media, pedagogy, Riskgaming, and science-policy communication.

Editorial partnershipsPublic policyResearchRiskgamingScience communicationStrategic messaging
Peter Hébert

Peter Hébert

Partner and Co-Founder

Lux Capital

Peter Hébert is Partner and Co-Founder at Lux Capital. His official profile says he helps lead the firm, invests across technology and healthcare, and launched Lux's Health + Tech investment strategy.

DeeptechFrontier technology
RP

Robert Paull

Co-Founder and Venture Partner

Lux Capital

Lux co-founder and healthcare venture partner with biotech CEO and company-formation experience.

BiotechHealthcareHealthcare ITInfectious diseaseNeurotechnologyOphthalmology